Respiratory syncytial virus: prospects for new and emerging therapeutics

References

• Ruckwardt TJ, Morabito KM, Graham BS. Determinants of early life immune responses to RSV infection. Curr Opinion Virol. 2016 Feb;16:151–157.
   PubMed Web of Science ®Google Scholar
• Jorquera PA, Anderson L, Tripp RA. Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis. Expert Rev Vaccines. 2016;15(2):173–187.
   PubMed Web of Science ®Google Scholar
• Abraha HY, Lanctot KL, Paes B. Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention. Expert Rev Respir Med. 2015;9(6):779–799.
   PubMed Web of Science ®Google Scholar
• Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–1555.
   PubMed Web of Science ®Google Scholar
• Afonso CL, Amarasinghe GK, Bányai K, et al. Taxonomy of the order Mononegavirales: update 2016. Arch Virol. 2016;161(8):2351–2360.
   PubMed Web of Science ®Google Scholar
• Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 2011;162(1–2):80–99.
   PubMed Web of Science ®Google Scholar
• Roberts JN, Graham BS, Karron RA, et al. Challenges and opportunities in RSV vaccine development: meeting report from FDA/NIH workshop. Vaccine. 2016;34(41):4843–4849.
   PubMed Web of Science ®Google Scholar
• Higgins D, Trujillo C, Keech C. Advances in RSV vaccine research and development - a global agenda. Vaccine. 2016;34(26):2870–2875.
   PubMed Web of Science ®Google Scholar
• Sun Z, Pan Y, Jiang S, et al. Respiratory syncytial virus entry inhibitors targeting the F protein. Viruses. 2013;5(1):211–225.
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, McClure MW, Symons JA, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med. 2015;373(21):2048–2058.
   PubMed Web of Science ®Google Scholar
• Perron M, Stray K, Kinkade A, et al. GS-5806 inhibits a broad range of respiratory syncytial virus clinical isolates by blocking the virus-cell fusion process. Antimicrob Agents Chemother. 2016;60(3):1264–1273.
   Web of Science ®Google Scholar
• Douglas JL, Panis ML, Ho E, et al. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob Agents Chemother. 2005;49(6):2460–2466.
   PubMed Web of Science ®Google Scholar
• Douglas JL, Panis ML, Ho E, et al. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J Virol. 2003;77(9):5054–5064.
   PubMed Web of Science ®Google Scholar
• McKimm-Breschkin J. VP-14637 ViroPharma. Curr Opin Investig Drugs. 2000;1(4):425–427.
   PubMedGoogle Scholar
• Wyde PR, Laquerre S, Chetty SN, et al. Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antiviral Res. 2005;68(1):18–26.
   PubMed Web of Science ®Google Scholar
• Samuel Israel, Sarah Rusch, John DeVincenzo, et al. Effect of oral JNJ-53718678 (JNJ-678) on disease severity in healthy adult volunteers experimentally inoculated with live respiratory syncytial virus (RSV): a placebo-controlled challenge study. ID week. In: Advancing science, improving care. Poster session(650). Conference: ID Week 2016, New Orleands, LA. 2016. https://idsa.confex.com/idsa/2016/webprogram/Paper59339.html.
   Google Scholar
• Draffan AG, Bond S, Fenner J, et al. Preclinical characterization of an orally bioavailable fusion inhibitor, BTA-C585, for the treatment of RSV infection. In: 4th interscience conference on antimicrobial agents and chemotherapy (ICAAC) meeting. Poster presentation number F-1576. Conference ICAAC 2014, Washington DC. 2014.
   Google Scholar
• Toovey S, Wu J, Wang V, et al. Safety and pharmacokinetics in healthy volunteers of the anti-RSV antiviral AK0529. In: 1st International meeting on respiratory pathogens. Singapore; 2015 Sep 3.
   Google Scholar
• Zamora MR, Budev M, Rolfe M, et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2011;183(4):531–538.
   PubMed Web of Science ®Google Scholar
• DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2010;107(19):8800–8805.
   PubMed Web of Science ®Google Scholar
• Gottlieb J, Zamora MR, Hodges T, et al. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transplant. 2016;35(2):213–221.
   PubMed Web of Science ®Google Scholar
• Huang K, Incognito L, Cheng X, et al. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol. 2010;84(16):8132–8140.
   PubMed Web of Science ®Google Scholar
• Forbes ML, Kumar VR, Yogev R, et al. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Hum Vaccin Immunother. 2014;10(10):2789–2794.
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Chen X, Kumar VR. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children. Hum Vaccin Immunother. 2014;10(10):2785–2788.
   PubMed Web of Science ®Google Scholar
• Lanari M, Vandini S, Arcuri S, et al. The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection. Clin Dev Immunol. 2013;2013:359683.
   PubMedGoogle Scholar
• Sivapalasingam S, Vandini S, Arcuri S, et al. Phase 1 study evaluating safety, tolerability, pharmacokinetics and immunogenicity of REGN2222 in healthy adults: a new human monoclonal RSV-F antibody for RSV prevention. Open Forum Infect Dis. 2015;2. Available from: https://idsa.confex.com/idsa/2015/webprogram/Paper53399.html
   Google Scholar
• Griffin MP, Khan AA, Esser MT, et al. Safety, tolerability, and pharmacokinetics of the respiratory syncytial virus-prefusion F-targeting monoclonal antibody with an extended half-life, MEDI8897, in healthy adults. Antimicrob. Agents Chemother. March 2017;61:3e01714-16.  doi:10.1128/AAC.01714-16.
   Web of Science ®Google Scholar
• Detalle L, Stohr T, Palomo C, et al. Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob Agents Chemother. 2015;60(1):6–13.
   PubMed Web of Science ®Google Scholar
• Van Heeke G, Allosery K, De Brabandere V, et al. Nanobodies® as inhaled biotherapeutics for lung diseases. Pharmacol Ther. 2017;169:47–56.
   PubMed Web of Science ®Google Scholar
• Hynicka LM, Ensor CR. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients. Ann Pharmacother. 2012;46(4):558–566.
   PubMed Web of Science ®Google Scholar
• Hebert MF, Guglielmo BJ. What is the clinical role of aerosolized ribavirin? Dicp. 1990;24(7–8):735–738.
   PubMedGoogle Scholar
• Fearns R, Deval J. New antiviral approaches for respiratory syncytial virus and other mononegaviruses: inhibiting the RNA polymerase. Antiviral Res. 2016;134:63–76.
   PubMed Web of Science ®Google Scholar
• Ouizougun-Oubari M, Pereira N, Tarus B, et al. A druggable pocket at the nucleocapsid/phosphoprotein interaction site of human respiratory syncytial virus. J Virol. 2015;89(21):11129–11143.
   PubMed Web of Science ®Google Scholar
• Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–385.
   PubMed Web of Science ®Google Scholar
• Siegel D, Hui HC, Doerffler E, et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem. 2017;60:1648–1661.
   PubMed Web of Science ®Google Scholar
• Noton SL, Nagendra K, Dunn EF, et al. Respiratory syncytial virus inhibitor AZ-27 differentially inhibits different polymerase activities at the promoter. J Virol. 2015;89(15):7786–7798.
   PubMed Web of Science ®Google Scholar
• Caly L, Li H-M, Jans D. Host factors modulating RSV infection: use of small interfering RNAs to probe functional importance. Methods Mol Biol. 2016;1442:93–117.
   PubMedGoogle Scholar
• Kipper S, Hamad S, Caly L, et al. New host factors important for respiratory syncytial virus (RSV) replication revealed by a novel microfluidics screen for interactors of matrix (M) protein. Mol Cell Proteomics. 2015;14(3):532–543.
   PubMed Web of Science ®Google Scholar
• Tripp RA, Mejias A, Ramilo O. Host gene expression and respiratory syncytial virus infection. Curr Top Microbiol Immunol. 2013;372:193–209.
   PubMed Web of Science ®Google Scholar
• Johnson SM, McNally BA, Ioannidis I, et al. Respiratory syncytial virus uses CX3CR1 as a receptor on primary human airway epithelial cultures. Plos Pathog. 2015;11(12):e1005318.
   PubMed Web of Science ®Google Scholar
• Stewart-Jones GBE, Thomas PV, Chen M, et al. A cysteine zipper stabilizes a pre-fusion F glycoprotein vaccine for respiratory syncytial virus. Plos One. 2015;10(6):e0128779.
   PubMed Web of Science ®Google Scholar
• McCurdy LH, Graham BS. Role of plasma membrane lipid microdomains in respiratory syncytial virus filament formation. J Virol. 2003;77(3):1747–1756.
   PubMed Web of Science ®Google Scholar
• Huong TN, Tan BH, Sugrue RJ. A proteomic-based workflow using purified respiratory syncytial virus particles to identify cellular factors as drug targets. Methods Mol Biol. 2016;1442:175–194.
   PubMedGoogle Scholar
• Cox R, Plemper RK. Structure-guided design of small-molecule therapeutics against RSV disease. Expert Opin Drug Discov. 2016 Apr 21;11(6):1-14.
   PubMed Web of Science ®Google Scholar
• Battles MB, Langedijk JP, Furmanova-Hollenstein P, et al. Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nat Chem Biol. 2016;12(2):87–93.
   PubMed Web of Science ®Google Scholar
• Donalisio M, Rusnati M, Cagno V, et al. Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide. Antimicrob Agents Chemother. 2012;56(10):5278–5288.
   PubMed Web of Science ®Google Scholar
• Hotard AL, Lee S, Currier MG, et al. Identification of residues in the human respiratory syncytial virus fusion protein that modulate fusion activity and pathogenesis. J Virol. 2015;89(1):512–522.
   PubMed Web of Science ®Google Scholar
• Joyce MG, Zhang B, Ou L, et al. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat Struct Mol Biol. 2016;23(9):811–820.
   PubMed Web of Science ®Google Scholar
• Boyington JC, Joyce MG, Sastry M, et al. Structure-based design of head-only fusion glycoprotein immunogens for respiratory syncytial virus. Plos One. 2016;11(7):e0159709.
   PubMed Web of Science ®Google Scholar
• Melero JA. Influence of antigen conformation and mode of presentation on the antibody and protective responses against human respiratory syncytial virus: relevance for vaccine development. Expert Rev Vaccines. 2016;15(10):1319–1325.
   PubMed Web of Science ®Google Scholar
• Bond S, Draffan AG, Fenner JE, et al. 1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidate. Bioorg Med Chem Lett. 2015;25(4):976–981.
   PubMed Web of Science ®Google Scholar
• Bond S, Draffan AG, Fenner JE, et al. The discovery of 1,2,3,9b-tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 1. Bioorg Med Chem Lett. 2015;25(4):969–975.
   PubMed Web of Science ®Google Scholar
• Ortega-Berlanga B, Musiychuk K, Shoji Y, et al. Engineering and expression of a RhoA peptide against respiratory syncytial virus infection in plants. Planta. 2016;243(2):451–458.
   PubMed Web of Science ®Google Scholar
• Samuel D, Xing W, Niedziela-Majka A, et al. GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein. Antimicrob Agents Chemother. 2015;59(11):7109–7112.
   PubMed Web of Science ®Google Scholar
• Perron M, Stray K, Kinkade A, et al. GS-5806 inhibits a broad range of respiratory syncytial virus clinical isolates by blocking the virus-cell fusion process. Antimicrob Agents Chemother. 2015;60(3):1264–1273.
   PubMed Web of Science ®Google Scholar
• De Clercq E. Chemotherapy of respiratory syncytial virus infections: the final breakthrough. Int J Antimicrob Agents. 2015;45(3):234–237.
   PubMed Web of Science ®Google Scholar
• Challa S, Scott AD, Yuzhakov O, et al. Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother. 2015;59(2):1080–1087.
   PubMed Web of Science ®Google Scholar
• Alvarez R, Elbashir S, Borland T, et al. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother. 2009;53(9):3952–3962.
   PubMed Web of Science ®Google Scholar
• Blake SM, Tanaka D, Bendz LM, et al. Evaluation of the financial and health burden of infants at risk for respiratory syncytial virus. Adv Neonatal Care. 2016 Dec 6. doi: 10.1097/ANC.0000000000000367.
   PubMedGoogle Scholar
• Gurnett-Bander A, Perez-Caballero D, Sivapalasingam S, et al. Human antibodies to respiratory syncytial virus F protein and methods of use thereof. I. Regeneron Pharmaceuticals, Editor. 2014. https://www.google.com/patents/US20140271653.
   Google Scholar
• McLellan JS. Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Curr Opin Virol. 2015;11:70–75.
   PubMed Web of Science ®Google Scholar
• Liuzzi M, Mason SW, Cartier M, et al. Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase. J Virol. 2005;79(20):13105–13115.
   PubMed Web of Science ®Google Scholar
• Sudo K, Miyazaki Y, Kojima N, et al. YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action. Antiviral Res. 2005;65(2):125–131.
   PubMed Web of Science ®Google Scholar
• Xiong H, Foulk M, Aschenbrenner L, et al. Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor. Bioorg Med Chem Lett. 2013;23(24):6789–6793.
   PubMed Web of Science ®Google Scholar
• Ito K, Kim Y-I, Brookes D, et al. Anti-viral activities of PC786, a novel inhibitor of respiratory syncytial virus L-protein polymerase. Open Forum Infect Dis. 2016;3(suppl_1):651. doi:https://doi.org/10.1093/ofid/ofw172.514.
   Google Scholar
• Tayyari F, Marchant D, Moraes TJ, et al. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med. 2011;17(9):1132–1135.
   PubMed Web of Science ®Google Scholar
• Malhotra R, Ward M, Bright H, et al. Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells. Microbes Infect. 2003;5(2):123–133.
   PubMed Web of Science ®Google Scholar
• Tripp RA, Jones LP, Haynes LM, et al. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol. 2001;2(8):732–738.
   PubMed Web of Science ®Google Scholar
• Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol. 2000;1(5):398–401.
   PubMed Web of Science ®Google Scholar
• Turner TM, Jones LP, Tompkins SM, et al. A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV. J Virol. 2013;87(19):10792–10804.
   PubMed Web of Science ®Google Scholar
• Barreira ER, Precioso AR, Bousso A. Pulmonary surfactant in respiratory syncytial virus bronchiolitis: the role in pathogenesis and clinical implications. Pediatr Pulmonol. 2011;46(5):415–420.
   PubMed Web of Science ®Google Scholar
• Rämet M, Hallman M. Surfactant proteins and respiratory syncytial virus. J Pediatr. 2010;157(5):866; author reply 866-7.
   PubMed Web of Science ®Google Scholar
• McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113–1117.
   PubMed Web of Science ®Google Scholar
• McLellan JS, Yang Y, Graham BS, et al. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011;85(15):7788–7796.
   PubMed Web of Science ®Google Scholar
• McKimm-Breschkin JL, Fry AM. Meeting report: 4th ISIRV antiviral group conference: novel antiviral therapies for influenza and other respiratory viruses. Antiviral Res. 2016;129:21–38.
   PubMed Web of Science ®Google Scholar
• Simões EAF, DeVincenzo JP, Boeckh M, et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis. 2015;211(Suppl 1):S1–S20.
   PubMed Web of Science ®Google Scholar